|
US2259698A
(en)
|
1938-05-07 |
1941-10-21 |
Rare Chemicals Inc |
Physiologically effective substance and process of preparing same
|
|
US2594323A
(en)
|
1948-07-22 |
1952-04-29 |
Upjohn Co |
24-substituted delta 5-cholene-3, 24-diols
|
|
US3079385A
(en)
|
1961-01-24 |
1963-02-26 |
Roussel Uclaf |
Novel process of preparation of polyhydroxylated pregnanes
|
|
US3206459A
(en)
|
1962-10-19 |
1965-09-14 |
Syntex Corp |
10alpha-pregnan-19-ol derivatives
|
|
JPS5324071B2
(enExample)
|
1974-04-30 |
1978-07-18 |
|
|
|
US4071625A
(en)
|
1974-05-13 |
1978-01-31 |
Richardson-Merrell Inc. |
19-Oxygenated-5α-androstanes for the enhancement of libido
|
|
CH628907A5
(en)
|
1975-10-10 |
1982-03-31 |
Hoffmann La Roche |
Process for the preparation of 24,25-dihydroxycholesterol derivatives
|
|
JPS5840960B2
(ja)
|
1976-12-28 |
1983-09-08 |
帝人株式会社 |
ヒドロキシコレステロ−ル立体異性体間の相互変換法
|
|
JPS54163565A
(en)
|
1978-06-09 |
1979-12-26 |
Teijin Ltd |
24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
|
|
JPS5735597A
(en)
|
1980-08-13 |
1982-02-26 |
Teijin Ltd |
25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
|
|
US4358406A
(en)
|
1981-07-27 |
1982-11-09 |
Wisconsin Alumni Research Foundation |
26,26,26,27,27,27-Hexafluoro-1α,25-dihydroxycholecalciferol and process for preparing same
|
|
JPS61254599A
(ja)
|
1985-05-07 |
1986-11-12 |
Sumitomo Pharmaceut Co Ltd |
コレステロ−ルのフツ素誘導体
|
|
JPS62187485A
(ja)
|
1986-02-13 |
1987-08-15 |
Teijin Ltd |
２４，２５−エポキシコレステロ−ル類の製造法
|
|
AU609927B2
(en)
|
1987-08-25 |
1991-05-09 |
Kelvin W. Gee |
Compositions and methods for alleviating stress, anxiety and seizure activity
|
|
US5232917A
(en)
|
1987-08-25 |
1993-08-03 |
University Of Southern California |
Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
|
|
US5376645A
(en)
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
EP0701444B1
(en)
|
1993-05-24 |
2010-04-07 |
Purdue Pharma Ltd. |
Methods and compositions for inducing sleep
|
|
IL110309A0
(en)
|
1993-07-15 |
1994-10-21 |
Univ Kentucky Res Found |
A method of protecting against neuron loss
|
|
DE4338316A1
(de)
|
1993-11-10 |
1995-05-11 |
Jenapharm Gmbh |
Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
|
|
PT752860E
(pt)
|
1994-02-14 |
2000-12-29 |
Euro Celtique Sa |
Androstanos e pregnanos para modulacao alosterica do receptor de gaba
|
|
TW385308B
(en)
|
1994-03-04 |
2000-03-21 |
Merck & Co Inc |
Prodrugs of morpholine tachykinin receptor antagonists
|
|
US5595996A
(en)
|
1994-10-25 |
1997-01-21 |
Merck & Co., Inc. |
7-substituted 4-aza cholanic acid derivatives and their use
|
|
CN1171114A
(zh)
|
1994-11-23 |
1998-01-21 |
科斯赛斯公司 |
用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系
|
|
JPH08268917A
(ja)
|
1995-03-31 |
1996-10-15 |
D D S Kenkyusho:Kk |
癌組織への移行性の高い制癌剤
|
|
CA2223996A1
(en)
|
1995-06-06 |
1996-12-19 |
Cocensys, Inc. |
Neuroactive steroids of the androstane and pregnane series
|
|
US5792635A
(en)
|
1995-06-07 |
1998-08-11 |
Magainin Pharmaceuticals, Inc. |
Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
|
|
US6645953B2
(en)
|
1995-06-23 |
2003-11-11 |
Novo Nordisk A/S |
Meiosis regulating compounds
|
|
ATE254628T1
(de)
|
1995-06-23 |
2003-12-15 |
Novo Nordisk As |
Meiose regulierende verbindungen.
|
|
US5888996A
(en)
|
1995-07-26 |
1999-03-30 |
Trustees Of Boston University |
Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
|
|
WO1997003677A1
(en)
|
1995-07-24 |
1997-02-06 |
Trustees Of Boston University |
Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
|
|
JPH09328498A
(ja)
|
1996-06-10 |
1997-12-22 |
Teijin Ltd |
２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
|
|
WO1998005337A1
(en)
|
1996-08-01 |
1998-02-12 |
Cocensys, Inc. |
Use of gaba and nmda receptor ligands for the treatment of migraine headache
|
|
DE19635525A1
(de)
|
1996-08-20 |
1998-02-26 |
Schering Ag |
7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
|
WO1999058497A1
(en)
|
1998-05-11 |
1999-11-18 |
Novo Nordisk A/S |
Substituted guanidines and diaminonitroethenes, their preparation and use
|
|
KR20010043558A
(ko)
|
1998-05-13 |
2001-05-25 |
한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 |
감수분열 조절 화합물
|
|
US8541600B2
(en)
|
1998-11-24 |
2013-09-24 |
Harbor Therapeutics, Inc. |
11-aza, 11-thia and 11-oxa sterol compounds and compositions
|
|
DE19917930A1
(de)
|
1999-04-15 |
2000-10-19 |
Schering Ag |
Ent-Steroide als selektiv wirksame Estrogene
|
|
RU2243232C2
(ru)
|
1999-04-29 |
2004-12-27 |
Еро-Сельтик С.А. |
3альфа-гидрокси-3бета-метоксиметил-21-гетероцикл-замещенные стероиды, фармацевтическая композиция, способ облегчения или профилактики бессонницы или погружения в наркоз
|
|
US6376530B1
(en)
|
1999-05-10 |
2002-04-23 |
Merck & Co., Inc. |
Cyclic amidines useful as NMDA NR2B antagonists
|
|
GB9910934D0
(en)
|
1999-05-11 |
1999-07-14 |
Res Inst Medicine Chem |
Chemical compounds
|
|
CN1098273C
(zh)
|
1999-11-12 |
2003-01-08 |
中国科学院上海有机化学研究所 |
高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物
|
|
GB0000228D0
(en)
|
2000-01-06 |
2000-03-01 |
Phytopharm Plc |
Fluoro substituted sapogenins and their use
|
|
GB0019290D0
(en)
|
2000-08-04 |
2000-09-27 |
Symphar Sa |
Methods for inducing apolipoprotein E secretion
|
|
GR1003861B
(el)
|
2000-12-29 |
2002-04-11 |
|
Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
|
|
GB0107822D0
(en)
|
2001-03-28 |
2001-05-23 |
Phytopharm Plc |
Sapogenin derivatives their synthesis and use methods based upon their use
|
|
US20070197484A1
(en)
|
2001-05-03 |
2007-08-23 |
Ching Song |
Method of treating disorder related to high cholesterol concentration
|
|
DK1392713T3
(da)
|
2001-05-03 |
2008-02-18 |
Univ Chicago |
Lever-X-receptoragonister
|
|
JP2005508368A
(ja)
|
2001-11-08 |
2005-03-31 |
ザ ユニバーシティー オブ シカゴ |
高コレステロール濃度に関連した疾患の治療方法
|
|
CA2468989A1
(en)
|
2001-12-07 |
2003-06-19 |
Daniel M. Schwartz |
Treatment for age-related macular degeneration
|
|
KR101130212B1
(ko)
|
2002-03-27 |
2012-04-13 |
파이토팜 피엘씨 |
사포게닌 및 그 유도체의 치료 방법 및 사용법
|
|
NZ547344A
(en)
|
2002-03-27 |
2007-11-30 |
Phytopharm Plc |
Therapeutic methods and uses of sapogenins and their derivatives
|
|
GB0216621D0
(en)
|
2002-07-17 |
2002-08-28 |
Imaging Res Solutions Ltd |
Imaging compounds
|
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
|
CA2506568A1
(en)
|
2002-11-22 |
2004-06-10 |
Merck & Co., Inc. |
2-[(4-benzyl)-1-piperidinyl)methyl]benzimidazole-5-ol derivatives as nr2b receptor antagonists
|
|
AU2003288231A1
(en)
|
2002-12-13 |
2004-07-09 |
Bayer Healthcare Ag |
Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
|
|
FR2850023B1
(fr)
|
2003-01-17 |
2007-04-06 |
Mapreg |
Medicaments pour le systeme nerveux
|
|
US20050142192A1
(en)
|
2003-10-15 |
2005-06-30 |
Wyeth |
Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
|
|
GB0403889D0
(en)
|
2004-02-21 |
2004-03-24 |
Univ Edinburgh |
Uses of er-beta modulators
|
|
US8604011B2
(en)
*
|
2004-09-27 |
2013-12-10 |
The Regents Of The University Of California |
Therapy for treatment of chronic degenerative brain diseases and nervous system injury
|
|
US20070032464A1
(en)
|
2004-10-08 |
2007-02-08 |
Shutsung Liao |
Methods of treating cancers
|
|
CA2585471A1
(en)
|
2004-11-01 |
2006-05-11 |
Seo Hong Yoo |
Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
|
|
CA2643732C
(en)
|
2006-02-27 |
2012-08-21 |
The Regents Of The University Of California |
Oxysterol compounds and the hedgehog pathway
|
|
CN101164540A
(zh)
|
2006-08-03 |
2008-04-23 |
中山大学 |
海洋甾体化合物在制备治疗神经元损伤药物中的应用
|
|
GB0619860D0
(en)
|
2006-10-06 |
2006-11-15 |
Birkeland Innovasjon As |
Treatment of insulin resistance and disorders associated therewith
|
|
WO2008057468A1
(en)
|
2006-11-02 |
2008-05-15 |
Curis, Inc. |
Small organic molecule regulators of cell proliferation
|
|
EP2097437B1
(en)
|
2006-11-21 |
2015-05-27 |
Umecrine Cognition AB |
The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
|
|
JP5587184B2
(ja)
|
2007-06-20 |
2014-09-10 |
オースペックス・ファーマシューティカルズ・インコーポレイテッド |
繊維症阻害剤としての置換ｎ−アリールピリジノン
|
|
GB0712494D0
(en)
|
2007-06-27 |
2007-08-08 |
Isis Innovation |
Substrate reduction therapy
|
|
WO2009059961A2
(en)
|
2007-11-06 |
2009-05-14 |
N.V. Organon |
A method of hormone suppression in humans
|
|
JP2011505357A
(ja)
|
2007-12-03 |
2011-02-24 |
ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア |
ヘッジホッグシグナル伝達、骨誘導、抗脂肪生成、及びｗｎｔシグナル伝達を活性するためのオキシステロール
|
|
WO2009090063A1
(en)
|
2008-01-16 |
2009-07-23 |
Jado Technologies Gmbh |
Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
|
|
AU2009206580A1
(en)
|
2008-01-25 |
2009-07-30 |
Merck Sharp & Dohme Corp. |
Quinolizidinone M1 receptor positive allosteric modulators
|
|
NZ589764A
(en)
|
2008-05-09 |
2012-10-26 |
Univ Emory |
NMDA receptor antagonists for the treatment of neuropsychiatric disorders
|
|
WO2010065709A2
(en)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Hydroxamic acid derivatives, preparation and therapeutic uses thereof
|
|
WO2010075282A1
(en)
|
2008-12-22 |
2010-07-01 |
University Of Washington |
Molecular inhibitors of the wnt/beta-catenin pathway
|
|
WO2010088414A2
(en)
|
2009-01-28 |
2010-08-05 |
Emory University |
Subunit selective nmda receptor potentiators for the treatment of neurological conditions
|
|
JP2013500986A
(ja)
|
2009-07-29 |
2013-01-10 |
ザ・ユニバーシティ・オブ・シカゴ |
肝臓ｘ受容体アゴニスト
|
|
WO2011028794A2
(en)
|
2009-09-01 |
2011-03-10 |
Lazarus Therapeutics, Inc. |
Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
|
|
FR2953138B1
(fr)
|
2009-12-02 |
2015-10-16 |
Assist Publ Hopitaux Marseille |
Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
|
|
WO2011092127A1
(en)
|
2010-01-26 |
2011-08-04 |
Bayer Schering Pharma Aktiengesellschaft |
14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
|
|
KR101692275B1
(ko)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
GB201008047D0
(en)
|
2010-05-14 |
2010-06-30 |
Ge Healthcare Ltd |
Method of synthesis
|
|
US20120035156A1
(en)
|
2010-08-09 |
2012-02-09 |
Daniela Alberati |
Combination of glyt1 compound with antipsychotics
|
|
US8969525B2
(en)
|
2010-11-09 |
2015-03-03 |
Enzo Life Sciences, Inc. |
Hydroxycholesterol immunoassay
|
|
US20150031655A1
(en)
|
2011-04-15 |
2015-01-29 |
University Of North Dakota |
Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
|
|
CA2874998A1
(en)
|
2011-05-27 |
2012-12-06 |
Cytocure Llc |
Methods, compositions, and kits for the treatment of cancer
|
|
EP2736919A4
(en)
|
2011-07-29 |
2015-01-14 |
Univ California |
NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
|
|
CN107936076B
(zh)
*
|
2011-09-08 |
2021-10-15 |
萨奇治疗股份有限公司 |
神经活性类固醇、组合物、及其用途
|
|
SG2014010417A
(en)
|
2011-10-07 |
2014-06-27 |
Takeda Pharmaceutical |
1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
|
|
CN113234114A
(zh)
*
|
2011-10-14 |
2021-08-10 |
萨奇治疗股份有限公司 |
3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
|
|
US20150119327A1
(en)
|
2012-04-25 |
2015-04-30 |
The Regents Of The University Of California |
Drug screening platform for rett syndrome
|
|
US9737522B2
(en)
|
2012-08-09 |
2017-08-22 |
Emory University |
NMDA receptor modulators and uses related thereto
|
|
PT2935307T
(pt)
|
2012-12-18 |
2018-07-31 |
Univ Washington |
Esteroides 19-alcoxi-17-substituídos neuroativos, úteis em métodos de tratamento
|
|
EP3309166A3
(en)
|
2013-01-23 |
2018-08-22 |
Sphaera Pharma Pvt. Ltd. |
11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
|
|
KR20150110787A
(ko)
|
2013-01-29 |
2015-10-02 |
노렉스, 인크. |
스피로-락탐 nmda 수용체 조절인자 및 그의 용도
|
|
MX362544B
(es)
*
|
2013-03-13 |
2019-01-24 |
Sage Therapeutics Inc |
Esteroides neuroactivos y metodos para su uso.
|
|
JP2016514967A
(ja)
*
|
2013-03-13 |
2016-05-26 |
セージ セラピューティクス， インコーポレイテッド |
神経刺激性ステロイド、組成物およびそれらの使用
|
|
KR20160060688A
(ko)
|
2013-09-25 |
2016-05-30 |
반 안델 리서치 인스티튜트 |
고도로 강력한 글루코코르티코이드
|
|
EP4306114A1
(en)
|
2014-06-18 |
2024-01-17 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
WO2016007762A1
(en)
|
2014-07-09 |
2016-01-14 |
Duke University |
Compositions and methods for the repair of myelin
|
|
RU2764702C2
(ru)
|
2014-10-07 |
2022-01-19 |
Сейдж Терапьютикс, Инк. |
Нейроактивные соединения и способы их применения
|
|
PL3319612T3
(pl)
|
2015-07-06 |
2021-12-20 |
Sage Therapeutics, Inc. |
Oksysterole i sposoby ich stosowania
|
|
EP3828194B1
(en)
|
2015-07-06 |
2025-04-16 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
HK1255500A1
(zh)
|
2015-07-06 |
2019-08-16 |
Sage Therapeutics, Inc. |
氧固醇及其使用方法
|
|
GB2557875A
(en)
|
2015-09-02 |
2018-07-04 |
Univ Swansea |
Diagnostic methods and kits
|
|
US20190330259A1
(en)
|
2016-04-01 |
2019-10-31 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
US10752653B2
(en)
|
2016-05-06 |
2020-08-25 |
Sage Therapeutics, Inc. |
Oxysterols and methods of use thereof
|
|
MD3481846T2
(ro)
|
2016-07-07 |
2021-11-30 |
Sage Therapeutics Inc |
24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
|
|
CA3030420C
(en)
|
2016-07-11 |
2025-11-18 |
Sage Therapeutics, Inc. |
C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
|
|
CN121085986A
(zh)
|
2016-09-30 |
2025-12-09 |
萨奇治疗股份有限公司 |
C7取代的氧固醇及其作为nmda调节剂的方法
|
|
TW202444381A
(zh)
*
|
2016-10-18 |
2024-11-16 |
美商賽吉醫療公司 |
氧固醇(oxysterol)及其使用方法
|
|
KR102521573B1
(ko)
|
2016-10-18 |
2023-04-14 |
세이지 테라퓨틱스, 인크. |
옥시스테롤 및 그의 사용 방법
|
|
WO2018170336A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
|
AU2018288883B2
(en)
|
2017-06-23 |
2022-06-02 |
Intercept Pharmaceuticals, Inc. |
Methods and intermediates for the preparation of bile acid derivatives
|
|
SG11202004329TA
(en)
|
2017-11-10 |
2020-06-29 |
Marinus Pharmaceuticals Inc |
Ganaxolone for use in treating genetic epileptic disoders
|
|
TW202523658A
(zh)
|
2019-05-24 |
2025-06-16 |
美商賽吉醫療公司 |
化合物、組合物及使用方法
|
|
JP2024544777A
(ja)
|
2021-12-13 |
2024-12-04 |
セージ セラピューティクス， インコーポレイテッド |
ハンチントン病の治療のための神経活性ステロイド
|
|
WO2023114224A1
(en)
|
2021-12-13 |
2023-06-22 |
Sage Therapeutics, Inc. |
Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
|